Featured Insight
Article: Accelerated Approvals in Oncology: Benefits, Risks, and the Way Forward With Dr. Jason Mouabbi, Dr. Ross Maclean, and Michael Glover
Accelerated FDA approvals are under scrutiny and at the center of many debates. Explore the complexities, benefits, and risks of accelerated approvals with Ross Maclean, EVP at PRECISIONheor & Head of Medical Affairs at Precision Value & Health, in an insightful discussion alongside Dr. Jason A. Mouabbi, Breast Medical Oncologist at MD Anderson.
Article: Doubling Down on Deep Customer Insights to Inform Value Demonstration
An expert view from Ross Maclean, Head of Medical Affairs and Jon Bambalas, SVP, Business Development, Precision Value & Health, on how insights from patient-level health insurance benefits data can serve the pharmaceutical industry – namely, how coverage insights can inform the generation of evidence to demonstrate to payers and providers the value of a specific treatment.
On Demand: Quantifying Health Equity Impact of Innovative Healthcare Interventions
The COVID-19 pandemic laid bare disparities in access to quality healthcare and resources that have led to poor outcomes among racial and ethnic minorities, socioeconomically vulnerable individuals, and populations in rural areas. With a renewed and keener scrutiny of health equity issues, the distributional consequences of a new intervention across subgroups should come to the forefront of discussions about value in health. Join Precision HEOR for a webinar about studying the health equity impacts of new interventions. We will outline the conceptual basis of how health interventions can affect health equity and consider distributional cost-effectiveness analysis with decision-analytic models as a practical approach to assess this quantitatively. We will discuss the evidence needs and typical gaps for new interventions and how to optimize the use of existing data. The discussion will conclude with a live Q&A.
Article: Doubling Down on Deep Customer Insights to Inform Value Demonstration
An expert view from Ross Maclean, Head of Medical Affairs and Jon Bambalas, SVP, Business Development, Precision Value & Health, on how insights from patient-level health insurance benefits data can serve the pharmaceutical industry – namely, how coverage insights can inform the generation of evidence to demonstrate to payers and providers the value of a specific treatment.
Poster Presentation: San Antonio Breast Cancer Symposium (SABCS) 2023
Gilead Sciences, Inc. will present new data at the San Antonio Breast Cancer Symposium (SABCS) 2023 supporting the use of Trodelvy® (sacituzumab govitecan-hziy) in certain metastatic triple-negative breast cancer (mTNBC) and pre-treated HR+/HER2- metastatic breast cancer (mBC) patients. Precision's research with Gilead Sciences on "Understanding Clinical Meaningfulness in Metastatic Breast Cancer Treatment Decision-Making" will be presented during Poster Session 1: Poster # PO1-10-06 on Wednesday, Dec. 6 at 12:00 PM. Co-authored by Meaghan Roach, Rozanne Wilson, Suepattra May-Slater, Melissa Maravic and Emily Freeman.
Short Courses: ISPOR EU 2023
Precision will be at ISPOR Europe November 12-15, 2023. Don't miss our two Short Courses.
On Demand: Quantifying Health Equity Impact of Innovative Healthcare Interventions
The COVID-19 pandemic laid bare disparities in access to quality healthcare and resources that have led to poor outcomes among racial and ethnic minorities, socioeconomically vulnerable individuals, and populations in rural areas. With a renewed and keener scrutiny of health equity issues, the distributional consequences of a new intervention across subgroups should come to the forefront of discussions about value in health. Join Precision HEOR for a webinar about studying the health equity impacts of new interventions. We will outline the conceptual basis of how health interventions can affect health equity and consider distributional cost-effectiveness analysis with decision-analytic models as a practical approach to assess this quantitatively. We will discuss the evidence needs and typical gaps for new interventions and how to optimize the use of existing data. The discussion will conclude with a live Q&A.
Webinar: Quantifying Health Equity Impact of Innovative Health Care Interventions
The COVID-19 pandemic laid bare disparities in access to quality healthcare and resources that have led to poor outcomes among racial and ethnic minorities, socioeconomically vulnerable individuals, and populations in rural areas. With a renewed and keener scrutiny of health equity issues, the distributional consequences of a new intervention across subgroups should come to the forefront of discussions about value in health. Join PRECISIONheor for a webinar about studying the health equity impacts of new interventions. We will outline the conceptual basis of how health interventions can affect health equity and consider distributional cost-effectiveness analysis with decision-analytic models as a practical approach to assess this quantitatively. We will discuss the evidence needs and typical gaps for new interventions and how to optimize the use of existing data. The discussion will conclude with a live Q&A.
On-Demand Webinar – A Novel Data and Analytics-Informed Approach to Launch Excellence
Launching a therapy has become increasingly challenging, with only 34% of launches meeting their year-one goals (Evaluate Pharma, McKinsey). In addition, launches have also become more complex, with additional stakeholders to consider as well as the careful navigation of siloed, enterprise-wide functions and dynamic, fragmented data solutions. Not surprisingly, the path to a successful launch can be very narrow.
Article: Accelerated Approvals in Oncology: Benefits, Risks, and the Way Forward With Dr. Jason Mouabbi, Dr. Ross Maclean, and Michael Glover
Accelerated FDA approvals are under scrutiny and at the center of many debates. Explore the complexities, benefits, and risks of accelerated approvals with Ross Maclean, EVP at PRECISIONheor & Head of Medical Affairs at Precision Value & Health, in an insightful discussion alongside Dr. Jason A. Mouabbi, Breast Medical Oncologist at MD Anderson.
Article: Doubling Down on Deep Customer Insights to Inform Value Demonstration
An expert view from Ross Maclean, Head of Medical Affairs and Jon Bambalas, SVP, Business Development, Precision Value & Health, on how insights from patient-level health insurance benefits data can serve the pharmaceutical industry – namely, how coverage insights can inform the generation of evidence to demonstrate to payers and providers the value of a specific treatment.
On Demand: Quantifying Health Equity Impact of Innovative Healthcare Interventions
The COVID-19 pandemic laid bare disparities in access to quality healthcare and resources that have led to poor outcomes among racial and ethnic minorities, socioeconomically vulnerable individuals, and populations in rural areas. With a renewed and keener scrutiny of health equity issues, the distributional consequences of a new intervention across subgroups should come to the forefront of discussions about value in health. Join Precision HEOR for a webinar about studying the health equity impacts of new interventions. We will outline the conceptual basis of how health interventions can affect health equity and consider distributional cost-effectiveness analysis with decision-analytic models as a practical approach to assess this quantitatively. We will discuss the evidence needs and typical gaps for new interventions and how to optimize the use of existing data. The discussion will conclude with a live Q&A.
Short Courses: ISPOR EU 2023
Precision will be at ISPOR Europe November 12-15, 2023. Don't miss our two Short Courses.
Workshops: ISPOR EU 2023
Precision will be at ISPOR Europe November 12-15, 2023. Don't miss our two Workshops.
Download Now: Precision October Events Calendar
The October Events Calendar is here! Get all the details on Precision at upcoming conferences, links to upcoming and on-demand webinars, and catch up on our latest thought leadership!
Download Now: Precision September Events Calendar
The September Events Calendar is here! Get all the details on Precision at upcoming conferences, links to upcoming and on-demand webinars, and catch up on our latest thought leadership!
Article: The Role of the Pharma Industry in Superseding Outdated Medical Practices
There has been and continues to be a surge in biotech innovation. But a pertinent question arises: how frequently are older, now outdated technologies phased out? Precision's Ross Maclean, Phil Cyr and Ray Roth discuss the reluctance to abandon practices and technologies despite the availability of newer, better alternatives, and list how biopharma can lead the way.
Implications of the Biden IRA on the value proposition of new drugs
Little attention is being focused on the impact the Inflation Reduction Act (IRA) may have on pharmaceutical R&D pipeline assets currently in Phase II or early Phase III of development. Precision's Kathy Lang and Ross Maclean outline challenges with assessing the true value of innovations that will have implications for IRA assessments, and propose suggestions around the importance of early planning to mitigate several elements of risk that manufacturers will face.
Presentation by Precision’s Laura Panattonian at ISPOR 2023 Named the Best General Podium Research Presentation
The presentation by Precision's Laura Panattoni of a study with Tom Flottemesch, Natalie Land and Patrick Sullivan and their colleagues at ISPOR 2023 was named the Best General Podium Research Presentation. With this study, Laura and her colleagues aimed to quantify preferences for first line treatment attributes and treatment profiles among physicians who treat patients with aUC in 5 European countries (France, Germany, Italy, Spain, and the UK) with a DCE. Overall survival was the dominant attribute driving physicians’ choice of first line therapy, indicating that future therapies for aUC will need to provide substantial survival benefit to influence prescribing preferences. Reach out to Laura to learn more about this study.
Download Now: Precision March Events Calendar
The March Events Calendar is here! Stay up to date with all of the upcoming Precision conferences, on-demand events and recent thought leadership!
Structured expert elicitation to inform long-term survival extrapolations using alternative parametric distributions: a case study of CAR T therapy for relapsed/ refractory multiple myeloma
New study demonstrates the feasibility of systematically integrating long-term survival estimates obtained from a formal expert elicitation study with empirical clinical trial data through a case study. Learn more about recent work of PRECISIONheor's Shannon Cope (co-primary author), Kevin Towle and Ali Mojebi and their co-authors.
Download Now: Precision November Events Calendar
Check out our November Events Calendar, and stay up to date with all of the upcoming and on-demand Precision events and thought leadership!
Download Now: Precision October Events Calendar
Check out our October Events Calendar, and stay up to date with all of the upcoming and on-demand Precision events and thought leadership!
Download Now: Precision September Events Calendar
Check out our September Events Calendar, and stay up to date with all of the upcoming and on-demand Precision events and thought leadership!
On-demand Webinar: Social Determinants of Health–Perspectives From the Academic, Provider, and Research Community
Moderated by Precision's Ross Maclean, our distinguished panel of experts provide key insights on why social determinants of health (SDOH) are critical factors to inform today's treatment planning, care delivery, health policy, health outcomes and value.
On-Demand Webinar: Wish I Knew Then What I Know Now–How Cell and Gene Therapies are Reshaping Commercialization Strategies
In this webinar, Carolyn Morgan of PRECISIONeffect moderates an expert panel exploring the challenges of commercializing a cell or gene therapy from industry trailblazers.
On-demand Webinar: A Novel Method to Improve Validity and Relevance Of Indirect Comparisons and Network Meta-Analysis
Watch PRECISIONheor’s Jeroen Jansen, and partner David Phillippo, as they provide an introduction to a novel method, called multilevel network meta-regression (ML-NMR). The method addresses several limitations with current methods, including synthesizing networks of any size and availability of IPD or aggregate studies, and – crucially for decision-making – producing estimates in any target population of interest.
On-demand Webinar: Using HEOR Methods to Reduce Health Inequalities
Moderated by Precision's Kelly Wilder, EVP, Strategic Business Development, PRECISIONheor’s Jason Shafrin, PhD, and Meena Venkatachalam, MSc, discuss their recently published blog in Health Affairs
Congratulations to Precision’s Jason Shafrin!
For the third consecutive year, Jason's blog, Healthcare Economist, has been listed as one of the Top 100 Economics Blogs by Intelligent Economist.
On-demand Webinar: Improving evidence synthesis methods
Moderated by Precision's Ross Maclean, Dr. Jeroen Jansen and Shannon Cope share their unique perspectives and solutions to tackling today's evidence synthesis and economic modeling challenges.
Download Now: Precision September Events Calendar
The September Events Calendar is here! Get all the details on Precision at upcoming conferences, links to upcoming and on-demand webinars, and catch up on our latest thought leadership!
Article: The Role of the Pharma Industry in Superseding Outdated Medical Practices
There has been and continues to be a surge in biotech innovation. But a pertinent question arises: how frequently are older, now outdated technologies phased out? Precision's Ross Maclean, Phil Cyr and Ray Roth discuss the reluctance to abandon practices and technologies despite the availability of newer, better alternatives, and list how biopharma can lead the way.
Implications of the Biden IRA on the value proposition of new drugs
Little attention is being focused on the impact the Inflation Reduction Act (IRA) may have on pharmaceutical R&D pipeline assets currently in Phase II or early Phase III of development. Precision's Kathy Lang and Ross Maclean outline challenges with assessing the true value of innovations that will have implications for IRA assessments, and propose suggestions around the importance of early planning to mitigate several elements of risk that manufacturers will face.
Download Now: Precision June Events Calendar
The June Events Calendar is here! Stay up to date with all of the upcoming Precision conferences, on-demand events and recent thought leadership!
Download Now: Precision May Events Calendar
The MayEvents Calendar is here! Stay up to date with all of the upcoming Precision conferences, on-demand events and recent thought leadership!
Download Now: Precision April Events Calendar
The April Events Calendar is here! Stay up to date with all of the upcoming Precision conferences, on-demand events and recent thought leadership!
